Phase 1 trial finds GT919 plus dexamethasone improves efficacy in relapsed/refractory multiple myeloma, suggesting potential in future treatments.
Key Points
GT919 demonstrates encouraging efficacy with an overall response rate of 36% in relapsed/refractory multiple myeloma patients.
Patients treated with GT919 ≥2 mg plus dexamethasone achieved a median progression-free survival of over 20 months, indicating robust antimyeloma activity.
Open-label, multicenter phase I trial utilized a 3+3 dose escalation design to evaluate the safety and tolerability of GT919 in R/R multiple myeloma.
Further evaluation is merited given the manageable safety profile observed in this initial cohort of patients.